Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression
- Authors
- Goel, S., Gupta, N., Walcott, B.P., Snuderl, M., Kesler, C.T., Kirkpatrick, N.D., Heishi, T., Huang, Y., Martin, J.D., Ager, E., Samuel, R., Wang, S., Yazbek, J., Vakoc, B.J., Peterson, R.T., Padera, T.P., Duda, D.G., Fukumura, D., and Jain, R.K.
- ID
- ZDB-PUB-130816-28
- Date
- 2013
- Source
- Journal of the National Cancer Institute 105(16): 1188-1201 (Journal)
- Registered Authors
- Peterson, Randall
- Keywords
- none
- MeSH Terms
-
- Angiogenesis Inhibitors/pharmacology
- Animals
- Antineoplastic Agents/pharmacology*
- Breast Neoplasms/blood supply
- Breast Neoplasms/pathology*
- Disease Progression
- Drug Synergism
- Enzyme Activation/drug effects
- Enzyme Inhibitors/pharmacology*
- Female
- Human Umbilical Vein Endothelial Cells
- Lung Neoplasms/prevention & control*
- Lung Neoplasms/secondary
- Mice
- Mice, Inbred C57BL
- Neovascularization, Pathologic/drug therapy*
- Nitric Oxide Synthase Type III/metabolism
- Receptor, TIE-2/metabolism
- Receptor-Like Protein Tyrosine Phosphatases, Class 3/antagonists & inhibitors*
- Xenograft Model Antitumor Assays
- Zebrafish
- Zebrafish Proteins/metabolism*
- PubMed
- 23899555 Full text @ J. Nat. Cancer Inst.
Background The solid tumor microvasculature is characterized by structural and functional abnormality and mediates several deleterious aspects of tumor behavior. Here we determine the role of vascular endothelial protein tyrosine phosphatase (VE-PTP), which deactivates endothelial cell (EC) Tie-2 receptor tyrosine kinase, thereby impairing maturation of tumor vessels.
Methods AKB-9778 is a first-in-class VE-PTP inhibitor. We examined its effects on ECs in vitro and on embryonic angiogenesis in vivo using zebrafish assays. We studied the impact of AKB-9778 therapy on the tumor vasculature, tumor growth, and metastatic progression using orthotopic models of murine mammary carcinoma as well as spontaneous and experimental metastasis models. Finally, we used endothelial nitric oxide synthase (eNOS)–deficient mice to establish the role of eNOS in mediating the effects of VE-PTP inhibition. All statistical tests were two-sided.
Results AKB-9778 induced ligand-independent Tie-2 activation in ECs and impaired embryonic zebrafish angiogenesis. AKB-9778 delayed the early phase of mammary tumor growth by maintaining vascular maturity (P < .01, t test); slowed growth of micrometastases (P < .01, χ2 test) by preventing extravasation of tumor cells (P < 0.01, Fisher exact test), resulting in a trend toward prolonged survival (27.0 vs 36.5 days; hazard ratio of death = 0.33, 95% confidence interval = 0.11 to 1.03; P = .05, Mantel–Cox test); and stabilized established primary tumor blood vessels, enhancing tumor perfusion (P = .03 for 4T1 tumor model and 0.05 for E0771 tumor model, by two-sided t tests) and, hence, radiation response (P < .01, analysis of variance; n = 7 mice per group). The effects of AKB-9778 on tumor vessels were mediated in part by endothelial nitric oxide synthase activation.
Conclusions Our results demonstrate that pharmacological VE-PTP inhibition can normalize the structure and function of tumor vessels through Tie-2 activation, which delays tumor growth, slows metastatic progression, and enhances response to concomitant cytotoxic treatments.